Christopher Gibson, Chief Executive Officer at RECURSION PHARMACEUTICALS, INC. (RXRX), sold 60,000 shares at $8.12 ($478K) on 2025-02-06, disclosed to the SEC on 2025-02-07.
Scheduled sale ($478k) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $7.68 | 20,000 | $154K | 32.1% |
| 2 | $8.12 | 20,000 | $162K | 33.9% |
| 3 | $8.12 | 20,000 | $162K | 33.9% |
| Total | $7.97 avg | 60,000 | $478K | 100% |
| Filing → |
| RXRX | SELL | 2026-05-08 | $135K | — | Filing → |
| RXRX | SELL | 2026-04-24 | $144K | — | Filing → |
| RXRX | SELL | 2026-04-08 | $124K | — | Filing → |